ArticlePloS one2026
Upregulation of RPLP1 in PBMCs as a screening biomarker for melanoma.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early detection of melanoma is essential for improving patient outcomes. This research aimed to identify upregulated gene expression in peripheral blood mononuclear cells (PBMCs) induced by secretory factors derived from melanoma cells. These gene alterations may serve as potential non-invasive biomarkers for melanoma detection. Melanoma gene expression profiles from NCBI database were analyzed using the bioinformatics tool (CU-DREAM). A total of 85 participants were enrolled in the study. Expression levels of seven candidate genes were evaluated in a coculture model using PBMCs from healthy participants (n = 5) and melanoma cell lines at 24, 48, and 72 hours by quantitative real-time polymerase chain reaction (qRT-PCR). Based on these findings, the upregulated gene was further examined in PBMC samples for clinical expression analysis, including melanoma patients (n = 15), patients with various cancer types (n = 35), and healthy controls (n = 30). Receiver operating characteristic (ROC) curve analysis was carried out to determine the diagnostic performance of the candidate gene. Among the seven candidate genes, RPLP1 mRNA expression showed statistically significant upregulation in PBMCs cocultured with both melanoma cell lines, A375 (p = 0.0328) and SK-MEL-28 (p = 0.0311), at 24 hours compared with PBMC controls. The RPLP1 expression in PBMC blood samples also showed upregulation in melanoma patients compared to healthy controls (p = 0.0006). RPLP1 upregulation demonstrated good discriminative performance in this cohort with 93.30% sensitivity, 70.00% specificity, and an area under the curve (AUC) of 0.813 (p < 0.0001). RPLP1 upregulation in PBMCs may reflect a cancer-associated signal with relative enrichment in melanoma. Although elevated expression was also observed in breast cancer PBMCs, RPLP1 may still have potential as a minimally invasive and cost-effective screening biomarker for melanoma, given its high sensitivity in this study cohort. Further validation in larger, independent cohorts is required before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.